Teva Releases Q2 2026 Aide Memoire

Teva Pharmaceutical Industries Ltd. announced the availability of its Q2 2026 Aide Memoire document to assist investors ahead of second quarter 2026 results, scheduled for release on July 29, 2026. The company also announced an upcoming conference call to discuss financial results. The article includes standard forward-looking statements and risk disclosures.

06/18/2026, 5:00 PM • GlobeNewswire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva Pharmaceutical has submitted a New Drug Application (NDA) to the FDA for ecopipam, a first-in-class dopamine D1 receptor antagonist for treating pediatric Tourette syndrome. The submission is supported by positive Phase 3 data published in JAMA Neurology, showing ecopipam significantly delayed time to relapse compared to placebo with a p-value of 0.008. If approved, ecopipam could be the first FDA-approved treatment for pediatric Tourette syndrome in over a decade.

06/18/2026, 4:57 PM • GlobeNewswire

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 5,222 shares for approximately $143,000 on June 8, 2026, reducing his holdings by 3.60%. While his remaining stake of 139,763 shares keeps his interests aligned with investors, the sale follows a pattern of regular dispositions over the past year. The company faces headwinds from an upcoming generic competition agreement with Teva Pharmaceuticals for its flagship drug Jelmyto starting September 2030, though growth in other products like Zusduri may offset losses.

06/14/2026, 11:14 AM • The Motley Fool

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

Teva Pharmaceutical has rebounded 97% in 12 months driven by its expanding biosimilars lineup and branded drugs like Austedo. However, the stock now trades at a fair 25x P/E ratio with 2026 revenue expected to be flat to lower. While biosimilars could grow to $800 million by 2027, the narrow-margin business faces intense competition and the easy gains may already be priced in. The analyst recommends watching but not buying.

06/12/2026, 4:05 PM • The Motley Fool

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Teva Pharmaceutical Industries has completed its acquisition of Emalex Biosciences for $700 million upfront, with potential milestone payments up to $200 million. The acquisition adds ecopipam, a first-in-class D1 receptor antagonist for pediatric Tourette syndrome, to Teva's pipeline. Phase 3 data was recently published in JAMA Neurology showing statistical significance versus placebo, with an NDA submission anticipated in the second half of 2026.

06/10/2026, 12:03 PM • Benzinga

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

The global generic drug market is projected to grow from USD 491.35 billion in 2024 to USD 926.54 billion by 2034, expanding at a CAGR of 6.55%. Growth is driven by increasing demand for cost-effective medicines, rising chronic diseases, and aging populations, particularly in North America and Asia-Pacific regions. However, the market faces challenges from low awareness, branded drug preference among practitioners, and limited rural distribution.

06/09/2026, 12:30 AM • GlobeNewswire

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva announced new clinical data from multiple studies demonstrating that AUSTEDO and AUSTEDO XR (deutetrabenazine) reduce symptoms in tardive dyskinesia patients across severity levels. The IMPACT-TD Registry showed improvements in abnormal involuntary movements and daily living activities in mild TD cases, while the RIM-TD study found over 50% of patients achieved clinically meaningful response by week 15, with additional improvements continuing with sustained treatment. A caregiver education initiative also improved TD diagnosis rates.

06/08/2026, 8:00 AM • GlobeNewswire

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

New data from Teva's IMPACT-TD Registry reveals a significant diagnostic gap in tardive dyskinesia (TD), with only 23% of young adults (ages 18-29) with mood disorders receiving formal TD diagnosis despite 85% experiencing moderate to severe impact. The study of 211 adults with TD and concomitant mood disorders found that younger patients experience high psychological burden and face an average 3.5-year delay in diagnosis, highlighting the need for improved clinical identification and treatment.

05/18/2026, 8:00 AM • GlobeNewswire

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Teva Pharmaceutical announced a $700 million acquisition of Emalex Biosciences to expand its late-stage pipeline with ecopipam, beating Q1 earnings expectations with adjusted EPS of 53 cents versus 48 cents consensus. The company reaffirmed 2026 guidance, plans $700 million in cost savings by 2027, and authorized a share buyback program, signaling confidence in its growth strategy.

04/29/2026, 1:52 PM • Benzinga

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Teva Pharmaceutical Industries announced a definitive agreement to acquire Emalex Biosciences for $700 million upfront, with up to $200 million in additional milestone payments. The acquisition adds ecopipam, a first-in-class dopamine D1 receptor antagonist for pediatric Tourette syndrome, to Teva's neuroscience pipeline. The drug has shown positive Phase 3 data and FDA Orphan Drug designation, with NDA submission anticipated in H2 2026. The transaction is expected to close by Q3 2026.

04/29/2026, 6:30 AM • Benzinga

Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma

The global dermatomycoses market is expected to experience significant growth through 2035, driven by rising superficial fungal infections, increased hygiene awareness, and a growing immunocompromised population. Market advancements include enhanced antifungal formulations, digital PCR diagnostics, and nanopharmaceuticals. Key challenges include antifungal resistance and systemic drug concerns, while opportunities lie in AI diagnostics and broad-spectrum antifungals. Major players include Kaken Pharma, Novartis, Glenmark, Sun Pharma, Teva, Bayer, and Galderma.

04/23/2026, 4:57 AM • GlobeNewswire

Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting

Biolojic Design announced preclinical data for BD200, a multibody-drug conjugate targeting Trop-2 and Nectin-4, showing superior uptake and cytotoxicity compared to approved single-target drugs. BD200 demonstrated strong anti-tumor activity across multiple cancer models and in resistance settings where other ADCs failed. The company expects to enter clinical trials in the second half of 2026.

04/17/2026, 3:00 PM • GlobeNewswire

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Teva Pharmaceuticals announced the launch of Home Ground™ Schizophrenia Community, a free online platform designed to support people living with schizophrenia and their care partners. The platform provides peer-driven resources, symptom tracking tools, emotional wellness support, and community events to address social isolation, which affects over 75% of people with psychotic disorders. The initiative was developed in collaboration with patients, care partners, and mental health advocacy groups.

04/15/2026, 8:00 AM • GlobeNewswire

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Teva Pharmaceuticals, Direct Relief, and the National Association of Free and Charitable Clinics announced a second round of $75,000 grants to each of 11 free and charitable clinics across Alabama, Mississippi, and Texas to expand mental health services. In 2025, these programs reached over 57,000 people with mental health services and conducted nearly 6,000 depression and anxiety screenings. The initiative, now in its fourth year with $4 million in total funding since 2022, has demonstrated significant impact in addressing mental health access barriers in underserved communities.

04/14/2026, 8:00 AM • GlobeNewswire

Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

04/10/2026, 4:43 AM • GlobeNewswire